# Lecture 13: Reproductive Pharmacology
## Unit 2.4: Reproductive System
---
## Learning Objectives
By the end of this lecture, students will be able to:
1. Describe the pharmacology of hormonal contraceptives
2. Explain drugs used in infertility treatment
3. Describe drugs affecting uterine motility
4. Explain hormone replacement therapy pharmacology
5. Describe drugs used for reproductive endocrine disorders
6. Explain the pharmacology of drugs used in pregnancy
---
## Section 1: Estrogens - Pharmacology and Clinical Applications
Estrogens are steroid hormones essential for female reproductive function, secondary sexual characteristics, and bone and cardiovascular health. Understanding their pharmacology enables rational therapeutic use.
Natural estrogens include estradiol (E2, the most potent and primary ovarian estrogen), estrone (E1, formed by peripheral aromatization, dominant postmenopausally), and estriol (E3, produced primarily by the placenta during pregnancy). Synthetic estrogens include ethinyl estradiol (EE), the most commonly used synthetic estrogen due to its oral bioavailability and potency, and mestranol (a prodrug converted to EE).
The mechanism of action involves classical genomic effects through intracellular estrogen receptors (ERα and ERβ). Estrogen diffuses across the cell membrane, binds its receptor in the cytoplasm or nucleus, and the ligand-receptor complex dimerizes and binds estrogen response elements (EREs) in DNA, modulating transcription of target genes. This process takes hours to days for full effect. Non-genomic effects occur rapidly (seconds to minutes) through membrane-associated receptors, affecting ion channels, kinase cascades, and nitric oxide synthesis. These rapid effects are particularly important in cardiovascular tissue.
Pharmacokinetics vary by formulation and route. Oral estradiol undergoes extensive first-pass hepatic metabolism, converting largely to estrone; this increases hepatic protein synthesis (including clotting factors) and affects lipid profiles. Oral EE resists first-pass metabolism due to the ethinyl group at C17, providing higher bioavailability but more pronounced hepatic effects. Transdermal estradiol bypasses first-pass metabolism, producing steady estradiol levels without the disproportionate hepatic effects, resulting in less VTE risk and no triglyceride elevation. Vaginal estrogen is absorbed systemically to varying degrees depending on the formulation; ultra-low-dose preparations have minimal systemic absorption.
Clinical uses include contraception (combined with progestins), menopausal hormone therapy, hypogonadism treatment, and atrophic vaginitis treatment with local preparations.
Adverse effects relate to estrogen's physiologic actions: nausea, breast tenderness, headache, and, importantly, increased synthesis of hepatic clotting factors leading to VTE risk (primarily with oral preparations). Prolonged unopposed estrogen increases endometrial cancer risk, necessitating progestogen in women with intact uterus.
Panel A: Natural and synthetic estrogen structures showing estradiol (E2, most potent), estrone (E1, postmenopausal dominant), estriol (E3, placental), and ethinyl estradiol (EE, synthetic with ethinyl group conferring oral stability and resisting first-pass metabolism). Panel B: Genomic mechanism showing estrogen entering cell, binding ER (alpha and beta isoforms), receptor dimerization, nuclear translocation, DNA binding at estrogen response elements, and gene transcription over hours to days, plus rapid non-genomic effects through membrane receptors activating kinase cascades and nitric oxide synthesis. Panel C: Pharmacokinetics comparison showing oral estradiol with extensive first-pass hepatic conversion to estrone and increased hepatic protein synthesis, oral EE resisting first-pass with higher bioavailability but more hepatic effects, and transdermal estradiol bypassing liver with steady levels and less VTE risk. Panel D: Clinical uses (contraception, menopausal HT, hypogonadism, atrophic vaginitis) and adverse effects (nausea, breast tenderness, headache, VTE risk from increased clotting factors with oral preparations, endometrial cancer risk with unopposed estrogen).
---
## Section 2: Selective Estrogen Receptor Modulators (SERMs)
Selective estrogen receptor modulators exhibit tissue-specific agonist and antagonist activity at estrogen receptors, providing therapeutic selectivity. This tissue selectivity results from differing ER isoform distributions across tissues and different cofactor recruitment with different SERM-receptor complexes.
Tamoxifen is the prototypical SERM and a cornerstone of breast cancer treatment. In breast tissue, tamoxifen acts as an estrogen antagonist, blocking the growth-promoting effects of estrogen on ER-positive breast cancer cells. In bone, tamoxifen acts as a partial agonist, providing some protection against osteoporosis. In the endometrium, tamoxifen acts as an agonist, stimulating proliferation and increasing endometrial cancer risk approximately 2-4 fold with prolonged use. In lipid metabolism, tamoxifen has favorable agonist effects, lowering LDL cholesterol. Tamoxifen undergoes hepatic metabolism by CYP2D6 to its active metabolite endoxifen; poor metabolizers or those taking CYP2D6 inhibitors may have reduced efficacy. Adverse effects include hot flashes (due to estrogen antagonism centrally), VTE risk, and endometrial hyperplasia and carcinoma.
Raloxifene shares tamoxifen's antagonist activity in breast and bone agonism but critically lacks the endometrial stimulation, making it a safer choice for osteoporosis treatment in women at high breast cancer risk. However, raloxifene worsens hot flashes and is not appropriate for symptomatic menopausal women.
Clomiphene is classified as a SERM but used for its hypothalamic effects in ovulation induction. By blocking estrogen receptors in the hypothalamus, clomiphene removes negative feedback, increasing GnRH and gonadotropin secretion. This stimulates follicular development in anovulatory women. Side effects include hot flashes, visual disturbances (mandating discontinuation), and multiple pregnancy risk (5-10%).
Ospemifene acts as a vaginal agonist while being neutral in breast and endometrium, making it useful for treatment of dyspareunia from genitourinary syndrome of menopause in women who cannot use local estrogen.
Panel A: SERM tissue selectivity concept explaining how differing ER isoform distributions (ERalpha, ERbeta) and cofactor recruitment with different SERM-receptor complexes produce tissue-specific agonist and antagonist activity. Panel B: Four-column comparison table for tamoxifen, raloxifene, clomiphene, and ospemifene showing activity in breast (all antagonist), uterus (tamoxifen agonist with cancer risk, raloxifene and ospemifene neutral), bone (tamoxifen and raloxifene agonist), hypothalamus (clomiphene antagonist), and vagina (ospemifene agonist). Panel C: Tamoxifen metabolism showing CYP2D6 conversion to active metabolite endoxifen (poor metabolizers or CYP2D6 inhibitors reduce efficacy), with adverse effects (hot flashes, VTE, endometrial hyperplasia/carcinoma risk 2-4 fold). Panel D: Clinical uses for each SERM: tamoxifen for ER-positive breast cancer, raloxifene for osteoporosis and breast cancer prevention (without endometrial stimulation but worsens VMS), clomiphene for ovulation induction (hypothalamic estrogen blockade increasing FSH), and ospemifene for GSM dyspareunia.
---
## Section 3: Progestogens
Progestogens include natural progesterone and synthetic progestins, all acting through the progesterone receptor to produce progestational effects on the endometrium and other tissues.
Progesterone, the natural hormone produced by the corpus luteum and placenta, prepares the endometrium for implantation, maintains pregnancy, and has systemic effects including mild sedation and thermogenic effects. Oral progesterone (micronized formulation) has improved bioavailability and is metabolized to neurosteroid metabolites that contribute to its sedative effects. Vaginal and intramuscular routes provide higher bioavailability for luteal support in IVF.
Synthetic progestins are more potent and have longer half-lives than progesterone. They are classified by their structural derivation. 19-nortestosterone derivatives (norethindrone, levonorgestrel, desogestrel, norgestimate, etonogestrel) retain variable androgenic activity. First-generation progestins (norethindrone, norethynodrel) have the most androgenic effects. Second-generation (levonorgestrel) have intermediate androgenicity. Third-generation (desogestrel, norgestimate) were designed to minimize androgenic effects. Pregnane derivatives (medroxyprogesterone acetate, megestrol) have minimal androgenicity. Spironolactone derivative drospirenone has unique anti-androgenic and anti-mineralocorticoid properties.
The mechanism involves binding to intracellular progesterone receptors (PR-A and PR-B), which then regulate gene transcription. Progestational effects include secretory transformation of the estrogen-primed endometrium, thickening of cervical mucus, decreased tubal motility, and suppression of gonadotropin secretion.
Clinical uses include contraception (combined or progestin-only), hormone therapy (endometrial protection), menstrual disorders (dysfunctional uterine bleeding, endometriosis), preterm birth prevention (17-hydroxyprogesterone caproate or vaginal progesterone in women with prior preterm birth or short cervix), and luteal phase support in IVF.
Adverse effects vary by progestin type and include irregular bleeding, mood changes, weight gain (particularly with DMPA), acne and hirsutism with androgenic progestins, and decreased HDL cholesterol with some progestins.
Panel A: Progesterone structure and synthetic progestin classification tree showing 19-nortestosterone derivatives (first-generation norethindrone, second-generation levonorgestrel, third-generation desogestrel/norgestimate), pregnane derivatives (MPA, megestrol), and spironolactone derivative (drospirenone with anti-androgenic/anti-mineralocorticoid properties). Panel B: Androgenicity spectrum from high (first-generation) to anti-androgenic (drospirenone), with mechanism showing progesterone receptor binding (PR-A, PR-B), nuclear translocation, and endometrial effects (secretory transformation, decidualization). Panel C: Formulations and routes including oral micronized progesterone (sedative neurosteroid metabolites), oral progestins, DMPA injection, LNG-IUD (local endometrial effect), and subdermal implant, with clinical uses (contraception, HT, menstrual disorders, preterm birth prevention, IVF luteal support). Panel D: Side effects correlated with progestin properties showing irregular bleeding, mood changes, weight gain (especially DMPA), acne and hirsutism with androgenic progestins, and decreased HDL with some formulations.
---
## Section 4: Hormonal Contraceptive Pharmacology
Hormonal contraceptives utilize the pharmacologic properties of estrogens and progestogens to prevent pregnancy through multiple mechanisms.
Combined hormonal contraceptives (estrogen plus progestin) achieve primary contraception through ovulation suppression. The continuous presence of exogenous estrogen and progestin suppresses pituitary gonadotropin secretion, preventing the mid-cycle LH surge necessary for ovulation. Secondary mechanisms include progestin-induced thickening of cervical mucus (impeding sperm penetration), altered tubal motility, and endometrial changes unfavorable for implantation.
Ethinyl estradiol, the most common estrogen component, provides cycle control (preventing breakthrough bleeding) and contributes to ovulation suppression. Lower doses (20-35 μg) are used to minimize estrogen-related adverse effects while maintaining efficacy. The progestin component provides the primary contraceptive effect; different progestins are selected based on their androgenic profile and other properties.
Progestin-only contraceptives rely primarily on cervical mucus thickening for methods like the traditional progestin-only pill, while higher-dose methods (DMPA, implant) also suppress ovulation. The levonorgestrel IUD exerts primarily local effects (cervical mucus, endometrial atrophy) with variable systemic absorption.
Drug interactions affecting contraceptive efficacy primarily involve CYP450 enzyme induction. Rifampin, the strongest inducer, dramatically increases contraceptive metabolism, requiring alternative methods. Certain anticonvulsants (phenytoin, carbamazepine, phenobarbital, primidone, topiramate at doses >200 mg) similarly reduce efficacy. Lamotrigine levels are decreased by hormonal contraceptives, potentially reducing seizure control. Most antibiotics do not significantly affect contraceptive efficacy; the old advice to use backup contraception with antibiotics is not evidence-based (except for rifamycins).
Emergency contraceptive pharmacology: Levonorgestrel 1.5 mg works primarily by delaying or inhibiting ovulation; it has no effect after ovulation has occurred. Ulipristal acetate, a selective progesterone receptor modulator, can delay ovulation even after the LH surge has begun, providing extended efficacy. Neither disrupts an established pregnancy.
Panel A: Combined hormonal contraceptive mechanism showing HPO axis suppression with exogenous estrogen and progestin blocking GnRH pulsatility and preventing LH surge/ovulation, plus cervical mucus thickening and endometrial changes as secondary mechanisms. Panel B: Estrogen and progestin contribution table showing estrogen providing cycle control and augmenting ovulation suppression, and progestin providing primary contraceptive effect, with progestin-only method spectrum (POP, DMPA, implant, LNG-IUD) and their varying mechanisms. Panel C: Drug interactions showing CYP450 induction pathway with rifampin (strongest inducer) and anticonvulsants (phenytoin, carbamazepine, phenobarbital, topiramate) accelerating contraceptive metabolism, lamotrigine levels decreased by hormonal contraceptives, and most antibiotics not affecting efficacy. Panel D: Emergency contraception mechanisms showing levonorgestrel delaying ovulation (no effect after ovulation) and ulipristal acetate (SPRM) delaying ovulation even after LH surge with extended 5-day window, neither disrupting established pregnancy.
---
## Section 5: Drugs for Infertility - Ovulation Induction
Ovulation induction employs drugs that directly or indirectly stimulate follicular development and ovulation in anovulatory women or produce multiple follicles for assisted reproduction.
Clomiphene citrate acts as an estrogen antagonist at the hypothalamus, blocking negative feedback and increasing endogenous FSH secretion. It is administered orally (50-150 mg daily on cycle days 5-9), is well-tolerated, and induces ovulation in approximately 80% of women with PCOS. Adverse effects include hot flashes, visual disturbances (rare, requiring discontinuation), mood changes, and anti-estrogenic effects on cervical mucus and endometrium that may impair fertility paradoxically. Multiple pregnancy rate is 5-10%.
Letrozole, an aromatase inhibitor, reduces estrogen synthesis by inhibiting conversion of androgens to estrogens, thereby releasing the hypothalamic-pituitary axis from negative feedback. Compared to clomiphene, letrozole produces higher live birth rates in PCOS (per the NICHD trial), has more favorable endometrial effects, and has a lower multiple pregnancy rate. Dosing is 2.5-7.5 mg daily on cycle days 3-7.
Gonadotropins provide direct ovarian stimulation. FSH preparations (follitropin alfa, follitropin beta, urofollitropin) and human menopausal gonadotropins (menotropins, containing FSH and LH) are administered by daily subcutaneous injection. They are used when oral agents fail, for IVF protocols, or in hypogonadotropic hypogonadism. Close monitoring with ultrasound and estradiol is required due to risks of ovarian hyperstimulation syndrome (OHSS) and multiple pregnancy (20-30% with non-IVF use).
Human chorionic gonadotropin (hCG), which shares the LH receptor, triggers final oocyte maturation and ovulation when follicles reach maturity (approximately 18-20 mm). It is administered as a single injection ("trigger shot") approximately 36 hours before planned oocyte retrieval or timed intercourse.
GnRH agonists (leuprolide, nafarelin), when given in pulsatile fashion, can restore ovulation in hypothalamic amenorrhea. When given continuously, they initially stimulate (flare) then suppress gonadotropin secretion through receptor downregulation; this continuous use is employed in IVF protocols to prevent premature LH surge and in conditions like endometriosis. GnRH antagonists (cetrorelix, ganirelix) provide immediate gonadotropin suppression without flare and are used in IVF protocols.
Panel A: Clomiphene citrate showing hypothalamic estrogen receptor blockade increasing GnRH/FSH, dosing (50-150 mg days 5-9), 80% ovulation rate in PCOS, and side effects (hot flashes, visual disturbances requiring discontinuation, anti-estrogenic cervical mucus/endometrial effects). Panel B: Letrozole showing aromatase inhibition reducing estrogen with FSH rising, dosing (2.5-7.5 mg days 3-7), advantages over clomiphene (higher live birth rate per NICHD trial, lower multiples, favorable endometrial effects). Panel C: Gonadotropins showing direct FSH/LH ovarian stimulation by daily injection, monitoring protocol (serial ultrasound and estradiol), OHSS and multiple pregnancy (20-30%) warnings, with hCG trigger when follicles reach 18-20 mm as LH surge equivalent. Panel D: GnRH agonists showing pulsatile administration restoring ovulation in hypothalamic amenorrhea versus continuous administration causing flare then suppression for IVF protocols and endometriosis, plus GnRH antagonists providing immediate suppression without flare.
---
## Section 6: Uterotonic Agents
Uterotonics stimulate uterine contraction and are essential for labor management and postpartum hemorrhage treatment.
Oxytocin, a peptide hormone from the posterior pituitary, is the primary uterotonic. It binds oxytocin receptors on myometrial cells, activating phospholipase C, increasing intracellular calcium, and causing smooth muscle contraction. Receptor expression increases throughout pregnancy, making the uterus increasingly sensitive to oxytocin at term. Clinical uses include labor induction and augmentation (IV infusion, titrated to achieve adequate contractions), active management of the third stage of labor (10 units IV or IM after placental delivery), and PPH treatment. Adverse effects include uterine hyperstimulation (excessive contraction frequency or duration, potentially causing fetal distress or uterine rupture), water intoxication with prolonged high-dose infusion (oxytocin has structural similarity to ADH), and hypotension with rapid IV bolus.
Prostaglandins are potent uterotonics. Dinoprostone (PGE2), available as vaginal insert or gel, is used for cervical ripening before labor induction. Misoprostol (PGE1 analog) has multiple uses: cervical ripening (vaginal or oral), PPH treatment (800-1000 μg rectally), and medical abortion (with mifepristone). Advantages include low cost, stability at room temperature, and multiple administration routes. Adverse effects include nausea, diarrhea, fever, and uterine hyperstimulation. Carboprost (15-methyl-PGF2α) is a potent uterotonic for refractory PPH (250 μg IM, may repeat), but is contraindicated in asthma due to bronchospasm risk.
Ergot alkaloids (methylergonovine, ergonovine) cause sustained uterine contraction through combined alpha-adrenergic and serotonin receptor agonism. Methylergonovine 0.2 mg IM is used for PPH. The critical contraindication is hypertension due to vasoconstrictive effects that can precipitate severe hypertension, stroke, or myocardial infarction.
Tranexamic acid, an antifibrinolytic, reduces PPH-related mortality when given within 3 hours of delivery (WOMAN trial). The dose is 1 g IV; it inhibits plasminogen activation, stabilizing clots.
Panel A: Oxytocin mechanism (receptor binding, PLC activation, increased intracellular calcium, contraction), receptor upregulation throughout pregnancy, uses (labor induction, third stage management, PPH), IV titration protocol, and adverse effects (uterine hyperstimulation, water intoxication with prolonged high-dose infusion, hypotension with rapid bolus). Panel B: Prostaglandins showing dinoprostone (PGE2, vaginal insert/gel for cervical ripening), misoprostol (PGE1 analog, multiple routes for cervical ripening, PPH, medical abortion, low cost, room temperature stable), and carboprost (15-methyl-PGF2alpha, potent PPH treatment contraindicated in asthma). Panel C: Ergot alkaloids showing methylergonovine (0.2 mg IM for sustained uterine contraction via alpha-adrenergic and serotonin receptor agonism) with critical hypertension contraindication due to vasoconstrictive effects, and comparison table of all agents (dose, route, contraindication, onset). Panel D: Tranexamic acid showing antifibrinolytic mechanism (inhibits plasminogen activation, stabilizes clots), 1g IV dose, PPH-related mortality reduction per WOMAN trial, and 3-hour administration window emphasis.
---
## Section 7: Tocolytic Agents
Tocolytics inhibit uterine contractions and are used to delay preterm delivery, primarily to allow administration of antenatal corticosteroids and facilitate maternal transport.
Calcium channel blockers, particularly nifedipine, are often first-line tocolytics. By blocking L-type calcium channels in myometrial smooth muscle, they reduce intracellular calcium and inhibit contraction. Nifedipine is administered orally (initial loading dose 20-30 mg, then 10-20 mg every 4-6 hours). It is effective, well-tolerated, and has a favorable safety profile. Adverse effects include hypotension, tachycardia, headache, and flushing. Concurrent use with magnesium sulfate should be avoided due to risk of profound hypotension and neuromuscular blockade.
Indomethacin, a prostaglandin synthetase inhibitor (COX inhibitor), reduces prostaglandin production, which is essential for uterine contractions. It is effective and well-tolerated but is limited to gestational ages less than 32 weeks due to fetal adverse effects. Prolonged use can cause premature closure of the ductus arteriosus (by inhibiting prostaglandin-mediated patency) and oligohydramnios (by reducing fetal urine output through renal prostaglandin effects). Dosing is typically a 50-100 mg loading dose followed by 25-50 mg every 6 hours for 48-72 hours maximum.
Magnesium sulfate inhibits smooth muscle contraction through multiple mechanisms, including antagonism of calcium entry and myosin light chain kinase inhibition. While once commonly used as a tocolytic, evidence for efficacy is limited, and its primary role is now neuroprotection (reducing cerebral palsy risk in preterm infants when delivery is anticipated before 32 weeks) and seizure prophylaxis in preeclampsia. Dosing for neuroprotection is a 4-6 g IV bolus followed by 1-2 g/hour maintenance. Adverse effects include flushing, nausea, weakness, and, at toxic levels, respiratory depression and cardiac arrest. Calcium gluconate is the antidote.
Beta-adrenergic agonists (terbutaline, ritodrine) relax smooth muscle through β2-receptor activation. Use is now limited due to maternal cardiovascular side effects (tachycardia, pulmonary edema, arrhythmias) and an FDA black box warning against terbutaline use for more than 48-72 hours or outpatient use.
Atosiban, an oxytocin receptor antagonist, is used in Europe but is not FDA-approved in the United States.
Panel A: Nifedipine showing calcium channel blocking mechanism (L-type channel in myometrium, reduced calcium entry), oral dosing protocol (20-30 mg loading, then 10-20 mg every 4-6 hours), efficacy and favorable safety profile, adverse effects (hypotension, tachycardia, flushing), and magnesium sulfate interaction warning (profound hypotension and neuromuscular blockade). Panel B: Indomethacin showing COX inhibition reducing prostaglandin synthesis, gestational age limit (less than 32 weeks) due to fetal ductus arteriosus constriction and oligohydramnios from reduced fetal urine output, and 48-72 hour maximum duration. Panel C: Magnesium sulfate showing calcium antagonism mechanism, primary current use for neuroprotection (less than 32 weeks, reducing cerebral palsy) and preeclampsia seizure prophylaxis rather than tocolysis, dosing (4-6g bolus, 1-2 g/hr), toxicity ladder (reflexes lost 8-10, respiratory depression 12-15, cardiac arrest 25-30 mEq/L), and calcium gluconate antidote. Panel D: Beta-agonists showing beta-2 receptor mechanism with terbutaline, FDA black box warning against use beyond 48-72 hours or outpatient use, cardiovascular adverse effects (tachycardia, pulmonary edema), and atosiban as oxytocin receptor antagonist used in Europe but not FDA-approved.
---
## Section 8: Anti-Progestins and Drugs for Medical Abortion
Anti-progestins and abortifacients represent an important pharmacologic class with applications in pregnancy termination and other conditions.
Mifepristone (RU-486) is a competitive progesterone receptor antagonist with high affinity for the receptor. By blocking progesterone action, it destabilizes the decidua, induces endometrial breakdown, and sensitizes the myometrium to prostaglandins. Uses include medical abortion (in combination with misoprostol), and at lower doses, emergency contraception (widely used outside the United States). Additionally, mifepristone has glucocorticoid receptor antagonist activity (used in Cushing syndrome) and, in research contexts, potential for fibroid treatment and other applications.
The medical abortion protocol for pregnancies up to 70 days uses mifepristone 200 mg orally followed 24-48 hours later by misoprostol 800 μg (vaginal, buccal, or sublingual). Efficacy exceeds 95% complete abortion. The mechanism is synergistic: mifepristone blocks progesterone support and primes the uterus, while misoprostol causes uterine contractions to expel the pregnancy. Side effects include cramping, bleeding (expected and necessary), nausea, and rarely infection.
Ulipristal acetate is a selective progesterone receptor modulator (SPRM) with mixed agonist-antagonist activity depending on the tissue and hormonal milieu. Its primary use is emergency contraception (30 mg single dose within 120 hours of unprotected intercourse), where it delays ovulation even after the LH surge has begun. Unlike levonorgestrel EC, ulipristal maintains efficacy through day 5 and in women with higher BMI. It was also investigated for fibroid treatment in Europe but was restricted due to rare hepatotoxicity.
Misoprostol pharmacology merits emphasis given its versatility. This PGE1 analog binds EP2 and EP3 receptors, causing uterine contraction, cervical softening, and gastrointestinal effects. Uses span medical abortion (with mifepristone), postabortion and postpartum hemorrhage treatment, cervical ripening before procedures, labor induction, and gastroprotection (its original FDA-approved indication as adjunct to NSAIDs). Routes include oral, vaginal, buccal, sublingual, and rectal.
Panel A: Mifepristone (RU-486) as competitive progesterone receptor antagonist showing mechanism (blocking PR, destabilizing decidua, sensitizing myometrium to prostaglandins), additional glucocorticoid receptor antagonist activity (Cushing syndrome use), and potential fibroid treatment applications. Panel B: Medical abortion protocol flowchart with mifepristone 200 mg oral on day 1, misoprostol 800 mcg on day 2-3 (vaginal, buccal, or sublingual), follow-up confirmation, and greater than 95% efficacy through synergistic mechanism (mifepristone primes, misoprostol expels). Panel C: Ulipristal acetate as selective progesterone receptor modulator with mixed agonist-antagonist activity, emergency contraception use (30 mg single dose within 120 hours), extended efficacy even after LH surge, and BMI advantage over levonorgestrel. Panel D: Misoprostol versatility as PGE1 analog binding EP2/EP3 receptors, with multiple uses (medical abortion, postpartum hemorrhage, cervical ripening, labor induction, gastroprotection) and multiple routes (oral, vaginal, buccal, sublingual, rectal).
---
## Section 9: Drugs for Reproductive Endocrine Disorders
Several drugs target specific reproductive endocrine abnormalities.
Dopamine agonists treat hyperprolactinemia by activating D2 receptors on lactotrophs, inhibiting prolactin synthesis and secretion. Cabergoline (0.25-1 mg twice weekly) is preferred due to longer half-life, better tolerability, and greater efficacy than bromocriptine. Bromocriptine (1.25-2.5 mg daily, titrated) is an alternative. Both effectively reduce prolactin levels, restore ovulation, and shrink prolactinomas. Adverse effects include nausea, orthostatic hypotension, and, with high doses used in Parkinson disease, cardiac valvulopathy (less concerning at doses for hyperprolactinemia).
Anti-androgens treat hyperandrogenism in PCOS and other conditions. Spironolactone (50-200 mg daily), primarily a mineralocorticoid receptor antagonist, also blocks androgen receptors and inhibits 5α-reductase. It is effective for hirsutism and acne. Teratogenicity (feminization of male fetuses) mandates reliable contraception. Finasteride (5 mg daily) inhibits 5α-reductase type 2, blocking conversion of testosterone to the more potent DHT, and is effective for hirsutism (off-label). Flutamide is a pure androgen receptor antagonist but hepatotoxicity limits use.
Metformin, while not directly affecting reproductive hormones, improves insulin sensitivity in PCOS, which reduces hyperinsulinemia, decreases ovarian androgen production, and may restore ovulation. It is considered adjunctive to lifestyle modification rather than first-line for ovulation induction.
GnRH agonists and antagonists treat endometriosis and fibroids. Leuprolide (continuous administration) suppresses gonadotropins, creating a hypoestrogenic state that causes atrophy of ectopic endometrium and fibroid shrinkage. Add-back therapy with low-dose estrogen-progestin prevents bone loss and vasomotor symptoms during prolonged use. Newer oral GnRH antagonists with add-back (elagolix, relugolix) provide partial suppression, balancing efficacy against hypoestrogenic side effects.
Danazol, a weak androgen, was historically used for endometriosis but is now rarely used due to androgenic side effects (acne, hirsutism, voice deepening, weight gain).
Panel A: Dopamine agonists showing D2 receptor activation on lactotrophs inhibiting prolactin secretion, cabergoline (preferred, longer half-life, better tolerability, twice weekly) versus bromocriptine (daily, alternative), uses for hyperprolactinemia and prolactinoma shrinkage, and adverse effects (nausea, orthostatic hypotension). Panel B: Anti-androgens showing spironolactone (50-200 mg, androgen receptor block plus 5-alpha-reductase inhibition) and finasteride (5 mg, blocking testosterone to DHT conversion), both effective for hirsutism with mandatory reliable contraception due to teratogenicity (male fetus feminization), plus metformin as insulin sensitizer reducing hyperinsulinemia and ovarian androgens in PCOS. Panel C: GnRH agonists (leuprolide) showing continuous administration causing initial flare then suppression through receptor downregulation, hypoestrogenic effects shrinking endometriosis and fibroids, and add-back therapy with low-dose estrogen-progestin preventing bone loss and VMS during prolonged use. Panel D: Oral GnRH antagonists (elagolix, relugolix) providing partial gonadotropin suppression balancing efficacy against hypoestrogenic side effects with integrated add-back, and danazol as historical weak androgen for endometriosis now rarely used due to androgenic side effects.
---
## Section 10: Drugs in Pregnancy - Safety Considerations
Prescribing during pregnancy requires careful consideration of fetal safety alongside maternal benefit. Understanding drug categories, known teratogens, and safe alternatives is essential.
The former FDA pregnancy categories (A, B, C, D, X) have been replaced by the Pregnancy and Lactation Labeling Rule (PLLR), which provides narrative descriptions of available data rather than oversimplified categories. However, the category concepts remain useful for understanding: Category X drugs are contraindicated (known teratogenicity, risks outweigh any benefit), Category D drugs have positive evidence of fetal risk but may be acceptable in life-threatening situations, and Categories A-C represent decreasing levels of human safety data.
Known teratogens that must be avoided include isotretinoin (causes CNS malformations, craniofacial abnormalities, cardiac defects, and thymic abnormalities; iPLEDGE program mandates pregnancy prevention), warfarin (nasal hypoplasia, stippled epiphyses, CNS abnormalities; particularly harmful in first trimester), ACE inhibitors and ARBs (fetal renal dysgenesis, oligohydramnios, pulmonary hypoplasia when used in second/third trimester), valproic acid (neural tube defects, cognitive impairment), methotrexate (aminopterin syndrome, multiple malformations), carbamazepine and phenytoin (fetal hydantoin syndrome), lithium (Ebstein anomaly, though risk lower than previously thought), thalidomide (phocomelia), and mycophenolate (facial and limb abnormalities).
Safe medications commonly used in pregnancy include acetaminophen (preferred analgesic), penicillins and cephalosporins (antibiotics of choice), erythromycin and azithromycin (safe macrolides), labetalol, nifedipine, and methyldopa (antihypertensives of choice), insulin (does not cross placenta; preferred for diabetes), inhaled corticosteroids and short-acting beta-agonists (for asthma), pyridoxine and doxylamine (for nausea), and ondansetron (limited data but widely used for hyperemesis).
Condition-specific treatments in pregnancy include betamethasone or dexamethasone for fetal lung maturity (corticosteroids that cross the placenta), penicillin G for GBS prophylaxis, Rh immune globulin (RhoGAM) for Rh-negative mothers, and magnesium sulfate for both preeclampsia seizure prophylaxis and fetal neuroprotection.
Panel A: Transition from former FDA pregnancy categories (A, B, C, D, X) to Pregnancy and Lactation Labeling Rule (PLLR) with narrative descriptions, noting Category X as contraindicated (known teratogenicity) and Category D as positive fetal risk but potentially acceptable in life-threatening situations. Panel B: Teratogen gallery showing isotretinoin (CNS/craniofacial/cardiac defects, iPLEDGE program), warfarin (nasal hypoplasia, stippled epiphyses, first trimester most harmful), ACE inhibitors/ARBs (fetal renal dysgenesis, oligohydramnios in second/third trimester), valproic acid (neural tube defects, cognitive impairment), methotrexate (multiple malformations), and thalidomide (phocomelia). Panel C: Safe medications table by indication: pain (acetaminophen), antibiotics (penicillins, cephalosporins, azithromycin), hypertension (labetalol, nifedipine, methyldopa), diabetes (insulin, does not cross placenta), asthma (inhaled corticosteroids, short-acting beta-agonists), and nausea (pyridoxine/doxylamine, ondansetron). Panel D: Pregnancy-specific treatments showing antenatal corticosteroids (betamethasone/dexamethasone for fetal lung maturity), GBS prophylaxis (penicillin G in labor), RhoGAM for Rh-negative mothers, and magnesium sulfate for seizure prophylaxis and fetal neuroprotection.
---
## Summary
Estrogens act through nuclear receptors (ERα, ERβ) to regulate gene transcription, with transdermal routes avoiding first-pass hepatic effects and VTE risk associated with oral routes.
SERMs provide tissue-selective effects: tamoxifen (breast antagonist, endometrial agonist), raloxifene (bone agonist without endometrial stimulation), clomiphene (hypothalamic antagonist for ovulation induction), ospemifene (vaginal agonist for GSM).
Progestogens act through progesterone receptors, with varying androgenic properties by generation. Uses include contraception, endometrial protection, and preterm birth prevention.
Contraceptive pharmacology: combined methods suppress ovulation via HPO negative feedback; progestin-only methods primarily thicken cervical mucus. Rifampin and certain anticonvulsants reduce efficacy through CYP450 induction.
Ovulation induction: letrozole (aromatase inhibitor, first-line for PCOS) and clomiphene (SERM) increase endogenous FSH; gonadotropins directly stimulate ovaries.
Uterotonics: oxytocin (primary agent for labor and PPH), prostaglandins (dinoprostone for ripening, misoprostol for multiple uses, carboprost contraindicating asthma), methylergonovine (contraindicated in hypertension).
Tocolytics: nifedipine (calcium channel blocker, often first-line), indomethacin (COX inhibitor, limited to <32 weeks), magnesium sulfate (primarily for neuroprotection).
Mifepristone (progesterone receptor antagonist) combined with misoprostol achieves medical abortion with >95% efficacy.
Drug safety in pregnancy: avoid known teratogens (isotretinoin, warfarin, ACE inhibitors, valproic acid); use established safe alternatives (penicillins, labetalol, insulin, acetaminophen).
---
## Key Terms
| Term | Definition |
|------|------------|
| SERM | Selective estrogen receptor modulator; tissue-specific agonist/antagonist |
| Ethinyl estradiol | Synthetic estrogen used in most combined contraceptives |
| Mifepristone | Progesterone receptor antagonist for medical abortion |
| Oxytocin | Peptide uterotonic for labor induction and PPH |
| Tocolytic | Drug that inhibits uterine contractions |
| Clomiphene | SERM used for ovulation induction |
| Letrozole | Aromatase inhibitor for ovulation induction in PCOS |
| GnRH agonist | Continuous use causes pituitary suppression after initial flare |
---
*This content is subject to the [MIT License](https://opensource.org/licenses/MIT). © 2024–2026 Hibbert School of Medicine.*